Clinical Trial Update: Study of Karenitecin (BNP1350) to Treat Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Karenitecin (BNP1350) in malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Neoplasm

Drugs mentioned

• Karenitecin

Snippet

Sponsor: BioNumerik Pharmaceuticals, Inc. | Conditions: Melanoma, Neoplasm | Phase 2 | Status: COMPLETED